The Stability and Bioequivalence of Tenofovir, Emtricitabine and Efavirenz (Atripla) in an Extemporaneously Prepared Oral Liquid Formulation Compared With the Commercially Available Tablet Formulation.

Trial Profile

The Stability and Bioequivalence of Tenofovir, Emtricitabine and Efavirenz (Atripla) in an Extemporaneously Prepared Oral Liquid Formulation Compared With the Commercially Available Tablet Formulation.

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Sep 2012

At a glance

  • Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 20 May 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 20 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 20 Feb 2010 Results presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top